corporate_fare

Viatris Innovation GmbH

Address: Gewerbestrasse 14

Sponsor Overview

assignment

Specializations

Cardiovascular Medicine

Research activity includes acute myocardial infarction and recurrent ischemic risk, with interest in early symptom-driven intervention and outcomes in patients vulnerable to another cardiac event.

Acute myocardial infarction
Recurrent myocardial ischemia
Symptom-triggered treatment

The cardiovascular portfolio centers on emergency cardiac care and prevention of further infarction in high-risk populations.

Autoimmune and Rheumatologic Disease

Clinical research focuses on systemic lupus erythematosus, including moderate to severe disease and longer-term disease control in adults receiving background therapy.

Systemic lupus erythematosus
Moderate to severe autoimmune disease
Disease activity reduction

The work reflects sustained interest in controlling inflammatory activity and improving management of chronic autoimmune disorders.

Immunomodulatory Therapeutics

Trials examine oral therapies directed at immune-mediated disease, with emphasis on treatment effects in lupus and maintenance of tolerability during continued use.

Immune system modulation
Oral immunotherapy
Long-term tolerability

This area highlights therapeutic development for chronic inflammatory conditions requiring ongoing disease management.

Clinical Pharmacology

Research also includes evaluation in healthy volunteers, supporting characterization of drug behavior and exposure in humans.

Healthy volunteer studies
Bioavailability assessment
Human pharmacokinetics

These studies contribute to the understanding of how candidate medicines are absorbed and handled in the body.

Sponsored Trials

Trial Name	Country	Status
A Phase I Study to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Volunteers	The Netherlands	Not Recruiting
Efficacy and Safety Evaluation of Subcutaneous Selatogrel in Preventing Recurrent Acute Myocardial Infarction in Post-AMI Patients	Austria Belgium Bulgaria Croatia Czechia Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Norway Poland Portugal Romania Slovakia Spain Sweden The Netherlands	Recruiting
Evaluation of Cenerimod Efficacy and Safety in Adults with Moderate-to-Severe Systemic Lupus Erythematosus: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study	Czechia Germany Poland Portugal Spain	Not Recruiting
Evaluation of Long-Term Safety and Tolerability of Cenerimod in Adults with Moderate-to-Severe Systemic Lupus Erythematosus on Background Therapy	Bulgaria Czechia France Germany Greece Poland Portugal Romania Spain	Recruiting
Phase 3 Study on the Efficacy and Safety of Cenerimod in Adults with Moderate-to-Severe Systemic Lupus Erythematosus	Bulgaria France Greece Poland Romania	Not Recruiting